BERKELEY, CA--(Marketwired - Feb 19, 2015) - Dynavax Technologies Corporation (
A live webcast of the presentation will be available by visiting the "Investors" section of the Dynavax website or may be reached directly at: http://www.veracast.com/webcasts/rbc/healthcare2015/74104424775.cfm.
About Dynavax
Dynavax, a clinical-stage biopharmaceutical company, uses TLR biology to discover and develop novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidate is HEPLISAV-B, a Phase 3 investigational adult hepatitis B vaccine. For more information visit www.dynavax.com.
Contact Information:
Contact:
Michael Ostrach
Chief Business and Principal Financial Officer
510-665-7257